Bone Marrow Purging

• 

  Subject Areas on Research

  • A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. 
  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. 
  • Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. 
  • Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. 
  • Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. 
  • Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model. 
  • Guanine arabinoside as a bone marrow-purging agent. 
  • High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. 
  • Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine. 
  • Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. 
  • Purging multidrug resistant cells from bone marrow. 
  • Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. 
  • Spermine dialdehyde, a novel ex vivo purging agent for both allogenic and autologous bone marrow transplantations. 
  • State of the art in umbilical cord transplantation. 
  • The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. 
  • Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. 
  • Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support. 
  • Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. 
  • Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. 
  • Uses of epoetin for anemia in oncology. 
• 

  Keywords of People

  • Chen, Jun, Professor of Medicine, Duke Cancer Institute